Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

Completed · Phase 2

Conditions studied: Spondylitis, Ankylosing

In brief

The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin. It blocks the action of tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid arthritis, and other inflammatory conditions. We will randomly assign patients to receive either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.

Key facts

Study ID
NCT00000433
Run by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
People needed
42
Starts
1999-10-01
Expected to finish
2002-03-01
Last updated by the study team
2007-01-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.